ATE493495T1 - Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen - Google Patents
Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungenInfo
- Publication number
- ATE493495T1 ATE493495T1 AT01972985T AT01972985T ATE493495T1 AT E493495 T1 ATE493495 T1 AT E493495T1 AT 01972985 T AT01972985 T AT 01972985T AT 01972985 T AT01972985 T AT 01972985T AT E493495 T1 ATE493495 T1 AT E493495T1
- Authority
- AT
- Austria
- Prior art keywords
- dna vaccines
- methods
- genetely
- engineered
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23107000P | 2000-09-08 | 2000-09-08 | |
US23137600P | 2000-09-08 | 2000-09-08 | |
US23144900P | 2000-09-08 | 2000-09-08 | |
US23140300P | 2000-09-08 | 2000-09-08 | |
PCT/US2001/028365 WO2002019968A2 (en) | 2000-09-08 | 2001-09-10 | Genetically engineered co-expression dna vaccines, construction methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE493495T1 true ATE493495T1 (de) | 2011-01-15 |
Family
ID=27499592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01972985T ATE493495T1 (de) | 2000-09-08 | 2001-09-10 | Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020193330A1 (de) |
EP (2) | EP2329846B1 (de) |
AT (1) | ATE493495T1 (de) |
AU (1) | AU2001292610A1 (de) |
DE (1) | DE60143755D1 (de) |
WO (1) | WO2002019968A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
WO2005090392A1 (en) * | 2004-03-16 | 2005-09-29 | Inist Inc. | Tat-based tolerogen compositions and methods of making and using same |
WO2006033665A1 (en) * | 2004-03-16 | 2006-03-30 | Inist Inc. | Tat-based vaccine compositions and methods of making and using same |
CA2490747A1 (en) * | 2002-06-21 | 2003-12-31 | Centocor, Inc. | Method for generating monoclonal antibodies |
WO2004085613A2 (en) * | 2003-03-19 | 2004-10-07 | Stratagene | Electrocompetent host cells |
EP1566439A1 (de) * | 2004-02-20 | 2005-08-24 | Nestec S.A. | Prophylaxe oder Behandlung von Obesitas |
WO2006078271A2 (en) * | 2004-04-20 | 2006-07-27 | The United States Of America As Represented By The Secretary Of The Navy | Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus |
CN100572541C (zh) * | 2007-05-28 | 2009-12-23 | 中国农业科学院兰州兽医研究所 | 口蹄疫病毒双效疫苗载体、其制备方法及应用 |
WO2008153733A2 (en) | 2007-05-29 | 2008-12-18 | Nature Technology Corporation | Vectors and methods for genetic immunization |
EP2527439B1 (de) * | 2007-12-11 | 2014-03-26 | The Scripps Research Institute | Zusammensetzungen und Verfahren in Verbindung mit mRNA-Translation-Enhancer-Elementen |
US9023363B2 (en) * | 2008-10-21 | 2015-05-05 | International Vaccine Institute | A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines |
AU2010230073B2 (en) | 2009-03-23 | 2016-05-26 | Pin Pharma, Inc. | Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides |
WO2012000188A1 (en) * | 2010-06-30 | 2012-01-05 | Tot Shanghai Rd Center Co., Ltd. | Recombinant tumor vaccine and method of producing such |
JP2014501726A (ja) * | 2010-11-25 | 2014-01-23 | イムネイト・ソシエテ・ア・レスポンサビリテ・リミテ | Nkt細胞によって認識されるエピトープの添加による、抗原免疫原性の調節 |
CN103596971B (zh) * | 2010-11-25 | 2016-10-12 | 伊姆耐特有限责任公司 | 通过删除由nkt细胞识别的表位来调整抗原免疫原性 |
US9663556B2 (en) | 2013-10-04 | 2017-05-30 | Pin Pharma, Inc. | Treatment of cancers with immunostimulatory HIV tat derivative polypeptides |
ES2829574T3 (es) * | 2016-11-01 | 2021-06-01 | Novo Nordisk As | Sistema de regulación de plásmidos basado en temperatura |
US11419928B2 (en) | 2017-10-25 | 2022-08-23 | The Johns Hopkins University | Methods and compositions for treating cancer |
US11279745B2 (en) | 2019-04-26 | 2022-03-22 | Novo Nordisk A/S | Tolerogenic DNA vaccine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5416017A (en) * | 1990-05-18 | 1995-05-16 | The Scripps Research Institute | Cholera toxin gene regulated by tissue-specific promoters |
IL101715A (en) * | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
EP0803573A1 (de) * | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe |
US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
ATE451386T1 (de) * | 2001-06-07 | 2009-12-15 | Wyeth Corp | Mutantenformen von cholera holotoxin als adjuvans |
-
2001
- 2001-09-10 US US09/950,335 patent/US20020193330A1/en not_active Abandoned
- 2001-09-10 AU AU2001292610A patent/AU2001292610A1/en not_active Abandoned
- 2001-09-10 EP EP10007008.5A patent/EP2329846B1/de not_active Expired - Lifetime
- 2001-09-10 AT AT01972985T patent/ATE493495T1/de not_active IP Right Cessation
- 2001-09-10 EP EP01972985A patent/EP1315816B1/de not_active Expired - Lifetime
- 2001-09-10 DE DE60143755T patent/DE60143755D1/de not_active Expired - Lifetime
- 2001-09-10 WO PCT/US2001/028365 patent/WO2002019968A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1315816B1 (de) | 2010-12-29 |
EP1315816A2 (de) | 2003-06-04 |
WO2002019968A2 (en) | 2002-03-14 |
US20020193330A1 (en) | 2002-12-19 |
DE60143755D1 (de) | 2011-02-10 |
EP1315816A4 (de) | 2006-05-17 |
EP2329846B1 (de) | 2014-11-12 |
WO2002019968A3 (en) | 2002-05-16 |
WO2002019968A9 (en) | 2002-07-25 |
AU2001292610A1 (en) | 2002-03-22 |
EP2329846A1 (de) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE493495T1 (de) | Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen | |
DK1951296T4 (da) | Celleafledte viral vacciner med lave niveauer af restcelle-DNA | |
PT1487485E (pt) | Adjuvantes de imidazoquinolina para vacinas de adn | |
WO2007024941A3 (en) | Polyvalent vaccine | |
DE60226911D1 (de) | Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten | |
EP4219566A3 (de) | Rekombinante rsv-antigene | |
ATE485056T1 (de) | Verbesserte impfstoffe | |
IL150602A (en) | Proteosome influenza vaccine, method for preparing such and use thereof | |
NZ593220A (en) | Immunostimulatory oligonucleotides | |
DE60039198D1 (de) | Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen | |
DE60232647D1 (de) | Vorrichtung zur abgabe einer vakzine | |
DK1796717T3 (da) | Kombinationsvaccine | |
ATE503491T1 (de) | Verbesserte anthraximpfstoffe und abgabeverfahren | |
DE60325838D1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine | |
DK1740206T3 (da) | PHEP, en aminosyrepermease af Staphylococcus Aureus | |
EP1667634A4 (de) | Anthrax-vakzine | |
ATE505482T1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
DK1074266T3 (da) | Levende svækkede bakterier til anvendelse i vaccine | |
WO2004073604A3 (en) | Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity | |
DE60238554D1 (de) | Vakzine gegen infektionskrankheiten | |
TH95334A (th) | การใช้ของวัคซีนสำหรับการรักษา/การป้องกันของการแพร่เชื้อของจุลชีพก่อโรค | |
TH87147B (th) | วัคซีนสำหรับการทำให้เกิดภูมิคุ้มกันที่ต้านเชื้อเฮลิโคแมคเตอร์ | |
TH87147A (th) | วัคซีนสำหรับการทำให้เกิดภูมิคุ้มกันที่ต้านเชื้อเฮลิโคแมคเตอร์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |